Advanced-therapy access, evaluated through treatment-center economics.

HealthPulse brings provider-side reimbursement experience, drawn from the founder's prior work negotiating directly with payers, to life-sciences organizations working on coverage-policy design, launch planning and outcomes-based agreement structures.

Discuss a decision

What an engagement covers.

Life-sciences companies bringing an advanced therapy to market

The question: How coverage policy, billing mechanics and outcomes-based agreements will interact at the state and payer level.
What HealthPulse examines: Coverage policy, provider billing mechanics and outcomes-based agreement terms, for the provider settings that will treat patients.
What you receive: A written assessment of how those terms are likely to pay out at the treating provider, and which terms drive the result.
The decision it supports: Launch planning, coverage-policy positions and agreement design, while the plan can still change.
Where it starts: One product and the setting where it will be given.

How engagements run, and what HealthPulse commits to

Matching work.

Client Assignment

Oncology payment and purchasing analysis

Decision: How purchasing routes compare under stated payment and cost assumptions, for a pharmaceutical company's oncology team deciding how its therapies are bought and paid for at treatment centers.
Work delivered: An analysis of each purchasing route against hospital payment rules, with every input traced to its source.
Use: Editable readouts for the client's leadership meetings, and an editable decision model for the client team to test scenarios.

See it in Selected Work

Coverage policy is decided in billing mechanics.

Complex-therapy access depends on how coverage policy, billing mechanics and outcomes-based agreements interact at the state and payer level. HealthPulse's comment to CMS on Cell and Gene Therapy Access Model continuity is a worked example of that analysis applied to live federal rulemaking.

HealthPulse's reading of Europe's outcome-linked CAR-T arrangements from the treatment center's side is published here. For a manufacturer, the point is the same: an arrangement works only if the centers that give the therapy can keep giving it.

Regulatory comment

HealthPulse's Comment to CMS

Submitted July 29, 2026 on Medicaid community engagement requirements and CGT Access Model continuity.

Read the comment

Research

HealthPulse Intelligence

Benchmarking and policy work, each item classified by what it establishes and what it does not.

Browse the research

Better before a launch than after one.

Coverage-policy and billing questions are cheaper to answer while the launch plan is still moving.

Discuss a decision